Shots:
- The P-III (ARISE) trial assessed Cobenfy (xanomeline & trospium chloride) vs PBO as an adj. therapy to atypical antipsychotics in adults with inadequately controlled schizophrenia symptoms; eligible pts could enter a 52wk. OLE study
- At Wk. 6, trial showed a PANSS score change (1EP) of -14.3 vs -12.2, which was not statistically significant, & changes in 2EPs, incl. PSP (+5.3 vs +5.9) & CGI-S score (-0.6 vs -0.5)
- In post-hoc analysis, the risperidone subgroup showed PANSS score change of -11.3 vs -12.3, while non-risperidone subgroup showed improvement of -15.1 vs -11.7; further analysis is underway, plus discussions with regulators are planned. Full data to be presented at future meetings Â
Ref: Businesswire | Image: BMS
Related News:- The US FDA Approves BMS’ Opdivo + Yervoy as 1L Treatment for Hepatocellular Carcinoma (HCC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
